Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Nov 2011

Domchek Susan M, Mitchell Gillian, Lindeman Geoffrey J, Tung Nadine M, Balmaña Judith, Isakoff Steven J, Schmutzler Rita, Audeh M William, Loman Niklas, Scott Clare, Friedlander Michael, Kaufman Bella, Garber Judy E, Tutt Andrew, Robson Mark E

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Enzyme Inhibitors
Share to BRCA1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Mutation

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Research Design

Source

Identifiers

PMID: 21931031
DOI: 10.1200/JCO.2011.36.8134

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.PMID 21931031Read ↗

New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistanceSemantic proximity Read ↗

Stumbling Blocks on the Path to Personalized Medicine in Breast Cancer: The Case of PARP Inhibitors for <i>BRCA1/2</i>-Associated CancersSemantic proximity Read ↗

Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designsSemantic proximity Read ↗

PARP inhibitors and their evolving role in breast cancer.Semantic proximity Read ↗

BRCA2: a 25-year journey from gene identification to targeted cancer treatment.Semantic proximity Read ↗

Triple-negative breast cancer: from none to multiple therapeutic targets in two decadesSemantic proximity Read ↗

Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints.Semantic proximity Read ↗

Targeted therapies for breast cancer.Semantic proximity Read ↗

[Novel target therapies used in breast cancer management].Semantic proximity Read ↗

Subtype and pathway specific responses to anticancer compounds in breast cancerSemantic proximity Read ↗

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.Semantic proximity Read ↗

Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.